» Articles » PMID: 30544754

A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2018 Dec 15
PMID 30544754
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

10-oxo-5-(3-(pyrrolidin-1-yl) propyl)-5,10-dihydroindeno [1,2-b] indol-9-yl propionate (LS-2-3j) is a new chemically synthesized indole compound and some related analogues are known to be inhibitors (such as alectinib and Ko143) of ATP-binding cassette (ABC) transporters, especially the ABC transporter subfamily B member 1 (ABCB1) and the ABC transporter subfamily G member 2 (ABCG2). This study aimed to evaluate the multidrug resistance (MDR) reversal effects and associated mechanisms of LS-2-3j in drug-resistant cancer cells. The inhibition of cell proliferation in tested agents was evaluated by the 3-(4,5-dimethylthiazol)-2,5-diphenyltetrazolium bromide (MTT) assay. Accumulation or efflux of chemotherapy drugs was analyzed by flow cytometry. The ATPase activity was measured using an ATPase activity assay kit. The mRNA transcripts and protein expression levels were detected by real-time PCR and Western blot, respectively. In this connection, LS-2-3j significantly enhanced the activity of chemotherapeutic drugs in MDR cells and could significantly increase the intracellular accumulation of doxorubicin (DOX) and mitoxantrone (MITX) by inhibiting the function of the efflux pumps in ABCB1- or ABCG2-overexpressing cells. Furthermore, reduced ATPase activity, mRNA transcription, and protein expression levels of ABCB1 and ABCG2 were observed in a concentration dependent manner in MDR cancer cells.

Citing Articles

Formulation, Characterization and Cytotoxicity Effects of Novel Thymoquinone-PLGA-PF68 Nanoparticles.

Noor N, Mohd Kaus N, Szewczuk M, Hamid S Int J Mol Sci. 2021; 22(17).

PMID: 34502328 PMC: 8431343. DOI: 10.3390/ijms22179420.


Inhibitors of Human ABCG2: From Technical Background to Recent Updates With Clinical Implications.

Toyoda Y, Takada T, Suzuki H Front Pharmacol. 2019; 10:208.

PMID: 30890942 PMC: 6411714. DOI: 10.3389/fphar.2019.00208.

References
1.
Ren X, Furukawa T, Aoki S, Nakajima T, Sumizawa T, Haraguchi M . Glutathione-dependent binding of a photoaffinity analog of agosterol A to the C-terminal half of human multidrug resistance protein. J Biol Chem. 2001; 276(25):23197-206. DOI: 10.1074/jbc.M101554200. View

2.
Gottesman M, Fojo T, Bates S . Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2(1):48-58. DOI: 10.1038/nrc706. View

3.
Borst P, Elferink R . Mammalian ABC transporters in health and disease. Annu Rev Biochem. 2002; 71:537-92. DOI: 10.1146/annurev.biochem.71.102301.093055. View

4.
Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N . NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene. 2003; 22(1):90-7. DOI: 10.1038/sj.onc.1206056. View

5.
Baker E, El-Osta A . The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer. Exp Cell Res. 2003; 290(2):177-94. DOI: 10.1016/s0014-4827(03)00342-2. View